Floatz logo

qeq278

Esophageal Squamous Cell Carcinoma

Novartis PharmaceuticalsPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

64 Active assets in the Esophageal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

qeq278 is also rated in:

renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →